FDA Readout Looms for ACHV, UNCY; Market Sees Split Odds
Achieve Life Sciences plunged 9.51% to $4.85 as its June 20 FDA deadline for cytisinicline passed with a manufacturing-related rejection expected; Unicycive Therapeutics dropped 2.84% to $6.85 ahead of a June 29 FDA decision, with both stocks’ applications limited by third-party manufacturing issues, not efficacy, and liquidity representing 39.7% and 31.2% of implied equity values, respectively.